SB 1257 — Uniform Controlled Dangerous Substances Act; modifying classification of certain substances. Effective date.

1257 Page 3 12.

“Counterfeit substance” means a controlled substance which, or the container or labeling of which without authorization, bears the trademark, trade name or other identifying marks, imprint, number or device or any likeness thereof of a manufacturer, distributor or dispenser other than the person who in fact manufactured, distributed or dispensed the substance;

“Deliver”"Deliver" or “delivery”"delivery" means the actual, constructive or attempted transfer from one person to another of a controlled dangerous substance or drug paraphernalia, whether or not there is an agency relationship;

“Dispense”"Dispense" means to deliver a controlled dangerous substance to an ultimate user or human research subject by or pursuant to the lawful order of a practitioner, including the prescribing, administering, packaging, labeling or compounding necessary to prepare the substance for such distribution.

“Dispenser”"Dispenser" is a practitioner who delivers a controlled dangerous substance to an ultimate user or human research subject;

“Distribute”"Distribute" means to deliver other than by administering or dispensing a controlled dangerous substance;

16.ENR.

“Distributor” means a commercial entity engaged in the distribution or reverse distribution of narcotics and dangerous drugs and who complies with all regulations promulgated by the federal Drug Enforcement Administration and the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;

ENGR.

1257 Page 43 17.16.

“Drug”"Distributor" means articles:a commercial entity engaged in the distribution or reverse distribution of narcotics and dangerous drugs and who complies with all regulations promulgated by the federal Drug Enforcement Administration and the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;

17.

"Drug" means articles:

“Drug"Drug paraphernalia”paraphernalia" means all equipment, products, and materials of any kind which are used, intended for use, or fashioned specifically for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling, or otherwise introducing into the human body, a controlled dangerous substance in violation of the Uniform Controlled Dangerous Substances Act including, but not limited to:

ENGR.a.

kits used, intended for use, or fashioned specifically for use in planting, propagating, cultivating, growing, or harvesting of any species of plant which is a controlled dangerous substance or from which a controlled dangerous substance can be derived, ENR.

1257 Page 54 a.b.

kits used, intended for use, or fashioned specifically for use in planting, propagating, cultivating, growing, or harvesting of any species of plant which is a controlled dangerous substance or from which a controlled dangerous substance can be derived, b.

diluents and adulterants, such as quinine hydrochloride, mannitol, mannite, dextrose, and lactose used, intended for use, or fashioned ENGR.specifically for use in cutting controlled dangerous substances, g.

S.

B.

NO.

1257 Page 6 specifically for use in cutting controlled dangerous substances, g.

capsules, balloons, envelopes, and other containers used, intended for use, or fashioned specifically for use in packaging small quantities of controlled dangerous substances, j.ENR.

containers and other objects used, intended for use, or fashioned specifically for use in parenterally injecting controlled dangerous substances into the human body, k.

hypodermic syringes, needles, and other objects used, intended for use, or fashioned specifically for use in parenterally injecting controlled dangerous substances into the human body, except as authorized by Section 2-1101 of this title, ENGR.

1257 Page 75 l.j.

containers and other objects used, intended for use, or fashioned specifically for use in parenterally injecting controlled dangerous substances into the human body, k.

hypodermic syringes, needles, and other objects used, intended for use, or fashioned specifically for use in parenterally injecting controlled dangerous substances into the human body, except as authorized by Section 2-1101 of this title, l.

(1) metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes with or without screens, permanent screens, hashish heads, or punctured metal bowls, (2) water pipes, (3) carburetion tubes and devices, (4) smoking and carburetion masks, (5) roach clips, meaning objects used to hold burning material, such as a marijuana cigarette, that has become too small or too short to be held in the hand, (6) miniature cocaine spoons and cocaine vials, (7) chamber pipes, (8) carburetor pipes, (9) electric pipes, (10) air-driven pipes, (11) chillums, (12)ENR. bongs, or (13) ice pipes or chillers, m.

all hidden or novelty pipes, and ENGR.

1257 Page 86 n.(12) bongs, or (13) ice pipes or chillers, m.

all hidden or novelty pipes, and n.

“Drug-dependent"Drug-dependent person”person" means a person who is using a controlled dangerous substance and who is in a state of psychic or physical dependence, or both, arising from administration of that controlled dangerous substance on a continuous basis.

“Harm-reduction"Harm-reduction services”services" means programs established to:

ENGR.a.

S.

B.

NO.

1257 Page 9 a.

21.ENR.

“HazardousS. materials” means materials, whether solid, liquid, or gas, which are toxic to human, animal, aquatic, or plant life, and the disposal of such materials is controlled by state or federal guidelines;

B.

NO.

1257 Page 7 21.

"Hazardous materials" means materials, whether solid, liquid, or gas, which are toxic to human, animal, aquatic, or plant life, and the disposal of such materials is controlled by state or federal guidelines;

“Home"Home care agency”agency" means any sole proprietorship, partnership, association, corporation, or other organization which administers, offers, or provides home care services, for a fee or pursuant to a contract for such services, to clients in their place of residence;

“Home"Home care services”services" means skilled or personal care services provided to clients in their place of residence for a fee;

“Hospice”"Hospice" means a centrally administered, nonprofit or for- profit, medically directed, nurse-coordinated program which provides a continuum of home and inpatient care for the terminally ill patient and the patient’spatient's family.

ENGR.A hospice program offers palliative and supportive care to meet the special needs arising out of the physical, emotional and spiritual stresses which are experienced during the final stages of illness and during dying and bereavement.

S.

B.

NO.

1257 Page 10 A hospice program offers palliative and supportive care to meet the special needs arising out of the physical, emotional and spiritual stresses which are experienced during the final stages of illness and during dying and bereavement.

“Class"Class A”A" Hospice refers to Medicare-certified hospices.

“Class"Class B”B" refers to all other providers of hospice services;

“Imitation"Imitation controlled substance”substance" means a substance that is not a controlled dangerous substance, which by dosage unit appearance, color, shape, size, markings or by representations made, would lead a reasonable person to believe that the substance is a controlled dangerous substance, or is a drug intended solely for veterinary purposes that is not a controlled dangerous substance and is being used outside of the scope of practice or normal course of business, as defined by the State Board of Veterinary Medical Examiners, or is a federal Food and Drug Administration-approved drug that is not a controlled dangerous substance and is being used outside the scope of approval for illicit purposes such as adulteratingENR. or lacing other controlled dangerous substances.

In the event the appearance of the dosage unit or use is not reasonably sufficient to establish that the substance is an imitation controlled substance, the court or authority concerned should consider, in addition to all other factors, the following factors:

ENGR.

1257 Page 118 a.adulterating or lacing other controlled dangerous substances.

In the event the appearance of the dosage unit or use is not reasonably sufficient to establish that the substance is an imitation controlled substance, the court or authority concerned should consider, in addition to all other factors, the following factors:

a.

“Immediate"Immediate precursor”precursor" means a substance which the Director has found to be and by regulation designates as being the principal compound commonly used or produced primarily for use, and which is an immediate chemical intermediary used, or likely to be used, in the manufacture of a controlled dangerous substance, the control of which is necessary to prevent, curtail or limit such manufacture;

“Initial"Initial prescription”prescription" means a prescription issued to a patient who:

ENGR.a.

has never previously been issued a prescription for the drug or its pharmaceutical equivalent in the past year, or ENR.

1257 Page 129 a.b.

has never previously been issued a prescription for the drug or its pharmaceutical equivalent in the past year, or b.

“Isomer”"Isomer" means the optical isomer, except as used in subsections C and F of Section 2-204 of this title and paragraph 4 of subsection A of Section 2-206 of this title.

“Laboratory”"Laboratory" means a laboratory approved by the Director as proper to be entrusted with the custody of controlled dangerous substances and the use of controlled dangerous substances for scientific and medical purposes and for purposes of instruction;

ENGR.30.

S."Manufacture" means the production, preparation, propagation, compounding or processing of a controlled dangerous substance, either directly or indirectly by extraction from substances of natural or synthetic origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis.

B."Manufacturer" includes any person who packages, repackages or labels any container of any controlled dangerous substance, except practitioners who dispense or compound prescription orders for delivery to the ultimate consumer;

NO.

1257 Page 13 30.

“Manufacture” means the production, preparation, propagation, compounding or processing of a controlled dangerous substance, either directly or indirectly by extraction from substances of natural or synthetic origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis.

“Manufacturer” includes any person who packages, repackages or labels any container of any controlled dangerous substance, except practitioners who dispense or compound prescription orders for delivery to the ultimate consumer;

“Marijuana”"Marijuana" means all parts of the Cannabis plant Cannabis sativa L., whether growing or not;

tetrahydrocannabinols, neutral compounds, and their corresponding acids, including synthetic equivalents of the substances contained in the Cannabis plant or in the resinous extractives of Cannabis, or synthetic substances, derivatives,ENR. and their isomers with similar chemical structure and pharmacological activity, but shall not include:

a.

the mature stalks of such plant or fiber produced from such stalks, b.

oil or cake made from the seeds of such plant, including cannabidiol derived from the seeds of the marijuana plant, ENGR.

1257 Page 1410 c.derivatives, and their isomers with similar chemical structure and pharmacological activity, but shall not include:

a.

the mature stalks of such plant or fiber produced from such stalks, b.

oil or cake made from the seeds of such plant, including cannabidiol derived from the seeds of the marijuana plant, c.

for any person or the parents, legal guardians or caretakers of the person who have received a written certification from a physician licensed in this state that the person has been diagnosed by a physician as having Lennox-Gastaut syndrome, Dravet syndrome, also known as severe myoclonic epilepsy of infancy, or any other severe form of epilepsy that is not adequately treated by traditional medical therapies, spasticity due to multiple sclerosis or due to paraplegia, intractable nausea and vomiting, appetite stimulation with chronic wasting diseases, the substance cannabidiol, a nonpsychoactive cannabinoid, found in ENGR.the Cannabis plant Cannabis sativa L.

or any other preparation thereof, that has a tetrahydrocannabinol concentration not more than three-tenths of one percent (0.3%) and that is delivered to the patient in the form of a liquid, ENR.

1257 Page 1511 theg. Cannabis plant Cannabis sativa L.

or any other preparation thereof, that has a tetrahydrocannabinol concentration not more than three-tenths of one percent (0.3%) and that is delivered to the patient in the form of a liquid, g.

“Medical"Medical purpose”purpose" means an intention to utilize a controlled dangerous substance for physical or mental treatment, for diagnosis, or for the prevention of a disease condition not in violation of any state or federal law and not for the purpose of satisfying physiological or psychological dependence or other abuse;

“Mid-level"Mid-level practitioner”practitioner" means an Advanced Practice Registered Nurse as defined and within parameters specified in Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified ENGR.animal euthanasia technician as defined in Section 698.2 of Title 59 of the Oklahoma Statutes, or an animal control officer registered by the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control under subsection B of Section 2-301 of this title within the parameters of such officer's duties under Sections 501 through 508 of Title 4 of the Oklahoma Statutes;

S.

B.

NO.

1257 Page 16 animal euthanasia technician as defined in Section 698.2 of Title 59 of the Oklahoma Statutes, or an animal control officer registered by the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control under subsection B of Section 2-301 of this title within the parameters of such officer’s duties under Sections 501 through 508 of Title 4 of the Oklahoma Statutes;

“Narcotic"Narcotic drug”drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

cocaine, its salts, optical and geometric isomers, and salts of isomers, d.ENR.

ecgonine, its derivatives, their salts, isomers and salts of isomers, and e.

a substance, and any compound, manufacture, salt, derivative or preparation thereof, which is chemically identical with any of the substances referred to in subparagraphs a through d of this paragraph, except that the words narcotic drug as used in Section 2-101 et seq.

of this title shall not include decocainized ENGR.

1257 Page 1712 cocad. leaves or extracts of coca leaves, which extracts do not contain cocaine or ecgonine;

ecgonine, its derivatives, their salts, isomers and salts of isomers, and e.

a substance, and any compound, manufacture, salt, derivative or preparation thereof, which is chemically identical with any of the substances referred to in subparagraphs a through d of this paragraph, except that the words narcotic drug as used in Section 2-101 et seq.

of this title shall not include decocainized coca leaves or extracts of coca leaves, which extracts do not contain cocaine or ecgonine;

“Opiate”"Opiate" or “opioid”"opioid" means any Schedule II, III, IV or V substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability.

“Opium"Opium poppy”poppy" means the plant of the species Papaver somniferum L., except the seeds thereof;

“Palliative"Palliative care”care" means a specialized medical service for people of any age and at any stage of a serious illness or life- altering medical event that focuses on navigating complex medical decisions while providing patient autonomy and access to information.

ENGR.38.

"Patient-provider agreement" means a written contract or agreement that is executed between a practitioner and a patient prior to the commencement of treatment for chronic pain using an opioid drug as a means to:

ENR.

1257 Page 1813 38.a.

“Patient-provider agreement” means a written contract or agreement that is executed between a practitioner and a patient prior to the commencement of treatment for chronic pain using an opioid drug as a means to:

a.

specify the measures the practitioner may employ to monitor the compliance of the patient including, but not limited to, random specimen screens and pill counts, and ENGR.f.

S.

B.

NO.

1257 Page 19 f.

“Peace"Peace officer”officer" means a police officer, sheriff, deputy sheriff, district attorney’sattorney's investigator, investigator from the Office of the Attorney General, or any other person elected or appointed by law to enforce any of the criminal laws of this state or of the United States;

40.ENR.

“Person” means an individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership or association, or any other legal entity;

41.

“Poppy straw” means all parts, except the seeds, of the opium poppy, after mowing;

42.

“Practitioner” means:

a.

(1) a medical doctor or osteopathic physician, (2) a dentist, ENGR.

1257 Page 2014 (3)40. a podiatrist, (4) an optometrist, (5) a veterinarian, (6) an Advanced Practice Registered Nurse under the supervision of a licensed medical doctor or osteopathic physician, or a physician assistant, (7) a scientific investigator, or (8) any other person, licensed, registered or otherwise permitted to prescribe, distribute, dispense, conduct research with respect to, use for scientific purposes or administer a controlled dangerous substance in the course of professional practice or research in this state, or b.

"Person" means an individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership or association, or any other legal entity;

41.

"Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing;

42.

"Practitioner" means:

a.

(1) a medical doctor or osteopathic physician, (2) a dentist, (3) a podiatrist, (4) an optometrist, (5) a veterinarian, (6) an Advanced Practice Registered Nurse under the supervision of a licensed medical doctor or osteopathic physician, or a physician assistant, (7) a scientific investigator, or (8) any other person, licensed, registered or otherwise permitted to prescribe, distribute, dispense, conduct research with respect to, use for scientific purposes or administer a controlled dangerous substance in the course of professional practice or research in this state, or b.

43.ENR.

“Production” includes the manufacture, planting, cultivation, growing or harvesting of a controlled dangerous substance;

44.

“Serious illness” means a medical illness or physical injury or condition that substantially affects quality of life for ENGR.

1257 Page 2115 more43. than a short period of time.

Serious"Production" illnessincludes includes,the butmanufacture, isplanting, notcultivation, limitedgrowing to, Alzheimer’s disease or relatedharvesting dementias,of lunga disease,controlled cancer,dangerous heartsubstance; failure, renal failure, liver failure, or chronic, unremitting, or intractable pain such as neuropathic pain;

44.

"Serious illness" means a medical illness or physical injury or condition that substantially affects quality of life for more than a short period of time.

Serious illness includes, but is not limited to, Alzheimer's disease or related dementias, lung disease, cancer, heart failure, renal failure, liver failure, or chronic, unremitting, or intractable pain such as neuropathic pain;

“State”"State" means the State of Oklahoma or any other state of the United States;

“Straw"Straw person”person" or “straw"straw party”,party", also known as a “front”,"front", means a third party who:

“Surgical"Surgical procedure”procedure" means a procedure that is performed for the purpose of structurally altering the human body by incision or destruction of tissues as part of the practice of medicine.

This term includes the diagnostic or therapeutic treatment of conditions or disease processes by use of instruments such as lasers, ultrasound, ionizing, radiation, scalpels, probes, or needles that ENGR.cause localized alteration or transportation of live human tissue by cutting, burning, vaporizing, freezing, suturing, probing, or manipulating by closed reduction for major dislocations or fractures, or otherwise altering by any mechanical, thermal, light- based, electromagnetic, or chemical means;

ENR.

1257 Page 2216 cause48. localized alteration or transportation of live human tissue by cutting, burning, vaporizing, freezing, suturing, probing, or manipulating by closed reduction for major dislocations or fractures, or otherwise altering by any mechanical, thermal, light- based, electromagnetic, or chemical means;

48.

“Synthetic"Synthetic controlled substance”substance" means a substance:

ENGR.b.

S.

B.

NO.

1257 Page 23 b.

(1) a controlled dangerous substance, (2) any substance for which there is an approved new drug application, (3) with respect to a particular person any substance, if an exemption is in effect for investigational use, for that person under the provisions of Section 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C., Section 355, toENR. the extent conduct with respect to such substance is pursuant to such exemption, or (4) any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance.

d.

Prima facie evidence that a substance containing salvia divinorum has been enhanced, concentrated, or chemically or physically altered shall give rise to a rebuttable presumption that the substance is a synthetic controlled substance;

ENGR.

1257 Page 2417 49.to the extent conduct with respect to such substance is pursuant to such exemption, or (4) any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance.

“Tetrahydrocannabinols”d. means includes all substances that have been chemically synthesized to emulate the tetrahydrocannabinols of marijuana, specifically including any tetrahydrocannabinols derived from industrial hemp;

Prima facie evidence that a substance containing salvia divinorum has been enhanced, concentrated, or chemically or physically altered shall give rise to a rebuttable presumption that the substance is a synthetic controlled substance;

49.

"Tetrahydrocannabinols" means includes all substances that have been chemically synthesized to emulate the tetrahydrocannabinols of marijuana, specifically including any tetrahydrocannabinols derived from industrial hemp;

“Ultimate"Ultimate user”user" means a person who lawfully possesses a controlled dangerous substance for the person’sperson's own use or for the use of a member of the person’sperson's household or for administration to an animal owned by the person or by a member of the person’sperson's household.

2021, Section 2-204, as last amended by Section 3,1 Chapterof 308,Enrolled O.S.L.House Bill No.

20243767 (63of O.S.the 2nd Session of the 60th Oklahoma Legislature, is amended to read as follows:

Supp.

2025, Section 2-204), is amended to read as follows:

ENGR.ENR.

1257 Page 2518 1.

22.ENR.

S.

B.

NO.

1257 Page 19 22.

ENGR.25.

S.

B.

NO.

1257 Page 26 25.

43.ENR.

S.

B.

NO.

1257 Page 20 43.

ENGR.

S.

NO.

1257 Page 27 B.

14.ENR.

S.

B.

NO.

1257 Page 21 14.

ENGR.21.

S.

B.

NO.

1257 Page 28 21.

2.ENR.

S.

B.

NO.

1257 Page 22 2.

ENGR.7.

S.

B.

NO.

1257 Page 29 7.

23.ENR.

S.

B.

NO.

1257 Page 23 23.

1-(1-(2-1-(1- thienyl)(2-thienyl) cyclohexyl) piperidine;

ENGR.28.

S.

B.

NO.

1257 Page 30 28.

42.ENR.

S.

B.

NO.

1257 Page 24 42.

ENGR.52.

S.

B.

NO.

1257 Page 31 52.

63.ENR.

S.

B.

NO.

1257 Page 25 63.

ENGR.76.

S.

B.

NO.

1257 Page 32 76.

84.ENR.

S.

B.

NO.

1257 Page 26 84.

ENGR.96.

S.

B.

NO.

1257 Page 33 96.

Tetrahydrocannabinol.Tetrahydrocannabinols.

3.ENR.

S.

B.

NO.

1257 Page 27 3.

ENGR.9.

1,4 Butanediol (1,4 BD or BDO) as packaged, marketed, manufactured, or promoted for human consumption with the exception of legitimate manufacturing purposes;

10.

N-ethylpentylone;

11.

Adinazolam;

12.

Meclonazepam;

13.

N-methylclonazepam;

14.

Bromazolam;

15.

Flunitrazolam;

16.

Nitrazolam;

17.

Pyrazolam;

18.

Zapizolam;

ENR.

1257 Page 3428 9.19.

1,4N-propionitrile Butanediolchlorphine; (1,4 BD or BDO) as packaged, marketed, manufactured, or promoted for human consumption with the exception of legitimate manufacturing purposes;

or20. 10.

N-ethylpentylone.5,6-dichloro desmethylchlorphine;

or 21.

Phenazolam.

gamma butyrolactone production, ENGR.n.

polybutylene terephthalate resin production, ENR.

1257 Page 3529 n.o.

polybutylene terephthalate resin production, o.

ENGR.F.

Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

ENR.

1257 Page 3630 F.1.

Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

1.

ENGR.17.

S.

B.

NO.

1257 Page 37 17.

22.ENR.

S.

B.

NO.

1257 Page 31 22.

ENGR.41.

S.

B.

NO.

1257 Page 38 41.

43.ENR.

S.

B.

NO.

1257 Page 32 43.

64.ENR.

JWH-211;

ENGR.

1257 Page 3933 65.64.

JWH-211;

65.

85.ENR.

S.

B.

NO.

1257 Page 34 85.

ENGR.89.

S.

B.

NO.

1257 Page 40 89.

106.ENR.

S.

B.

NO.

1257 Page 35 106.

ENGR.113.

S.

B.

NO.

1257 Page 41 113.

127.ENR.

S.

B.

NO.

1257 Page 36 127.

ENGR.137.

S.

B.

NO.

1257 Page 42 137.

148.ENR.

S.

B.

NO.

1257 Page 37 148.

any compound containing a 3-(1- naphthoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, ENGR.alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl- 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the naphthyl ring to any extent.

S.

B.

NO.

1257 Page 43 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl- 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the naphthyl ring to any extent.

1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015), g.ENR.

S.

B.

NO.

1257 Page 38 g.

1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412), ENGR.o.

S.

B.

NO.

1257 Page 44 o.

any compound containing a 3-(1- naphthoyl)pyrrole structure with or without substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl,ENR. 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on ENGR.

1257 Page 4539 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the pyrrole ring to any extent, and whether or not substituted on the naphthyl group to any extent.

any compound containing a 3- phenylacetylindole structure with or without substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1- ENGR.(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl- 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl ring to any extent.

Phenylacetylindoles include, but are not limited to:

a.

1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250), ENR.

1257 Page 4640 (N-methyl-2-piperidinyl)methyl,b. 2-(4-morpholinyl)ethyl, 1-(N-methyl- 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl ring to any extent.

Phenylacetylindoles include, but are not limited to:

a.

1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250), b.

ENGR.a.

S.

B.

NO.

1257 Page 47 a.

any compound containing a 3-(benzoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl- 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl groupENR. to any extent.

S.

B.

NO.

1257 Page 41 group to any extent.

1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or ENGR.e.

S.

B.

NO.

1257 Page 48 e.

Any compound containing a 1H-Indole-3- carboxamide structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl- 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- ENGR.pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, ENR.

1257 Page 4942 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl- 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3- dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent.

N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006), or ENGR.h.

S.

B.

NO.

1257 Page 50 h.

Any compound containing a 1H-Indole-3- carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl- 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate groupENR. by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl- 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3- dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.

S.

B.

NO.

1257 Page 43 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl- 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3- dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.

quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3- carboxylate (BB-22), ENGR.d.

S.

B.

NO.

1257 Page 51 d.

12.ENR.

Carbazole Ketone:

Any compound containing (9H-carbazole-3- yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl- ENGR.

1257 Page 5244 2-pyrrolidinyl)methyl,12. 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl- 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3- dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.

Carbazole KetonesKetones: include, but are not limited to, naphthalen-1-yl(9-pentyl- 9H-carbazol-3-yl)methanone (EG-018);

Any compound containing (9H-carbazole- 3-yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino- 3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1- methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.

Carbazole Ketones include, but are not limited to, naphthalen-1- yl(9-pentyl-9H-carbazol-3-yl)methanone (EG-018);

Benzimidazole Ketone:Ketones:

Any compound containing (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl- 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3- dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not ENGR.further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.

S.

B.

NO.

1257 Page 53 further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.

and 14.ENR.

Modified by Replacement:

any compound defined in this subsection that is modified by replacement of a carbon with nitrogen in the indole, naphthyl, indene, benzimidazole, or carbazole ring.

H.

Any prescription drug approved by the federal Food and Drug Administration under the provisions of Section 505 of the Federal Food, Drug, and Cosmetic Act, Title 21 of the United States Code, Section 355, that is designated, rescheduled, or deleted as a controlled substance under federal law by the United States Drug Enforcement Administration shall be excluded from Schedule I and shall be prescribed, distributed, dispensed, or used in accordance with federal law upon the issuance of a notice, final rule, or interim final rule by the United States Drug Enforcement Administration designating, rescheduling, or deleting as a controlled substance such a drug product under federal law, unless and until the State Board of Pharmacy takes action pursuant to Section 2-201 of this title.

If the Board of Pharmacy does not take action pursuant to Section 2-201 of this title, the drug product ENGR.

1257 Page 5445 shall14. be deemed to be designated, rescheduled, or deleted as a controlled substance in accordance with federal law and in compliance with the Uniform Controlled Dangerous Substances Act.

Modified by Replacement:

any compound defined in this subsection that is modified by replacement of a carbon with nitrogen in the indole, naphthyl, indene, benzimidazole, or carbazole ring.

H.

Any prescription drug approved by the federal Food and Drug Administration under the provisions of Section 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C., Section 355, that is designated, rescheduled, or deleted as a controlled substance under federal law by the United States Drug Enforcement Administration shall be excluded from Schedule I and shall be prescribed, distributed, dispensed, or used in accordance with federal law upon the issuance of a notice, final rule, or interim final rule by the United States Drug Enforcement Administration designating, rescheduling, or deleting as a controlled substance such a drug product under federal law, unless and until the State Board of Pharmacy takes action pursuant to Section 2-201 of this title.

If the State Board of Pharmacy does not take action pursuant to Section 2-201 of this title, the drug product shall be deemed to be designated, rescheduled, or deleted as a controlled substance in accordance with federal law and in compliance with the Uniform Controlled Dangerous Substances Act.

Any material, compound, mixture, or preparation which contains any quantity of the following hormonal substances or steroids, including their salts, isomers, esters and salts of isomersENR. and esters, when the existence of these salts, isomers, esters, and salts of isomers and esters is possible within the specific chemical designation:

a.

Boldenone, b.

Chlorotestosterone, ENGR.

1257 Page 5546 c.isomers and esters, when the existence of these salts, isomers, esters, and salts of isomers and esters is possible within the specific chemical designation:

a.

Boldenone, b.

Chlorotestosterone, c.

Norethandrolone, t.ENR.

S.

B.

NO.

1257 Page 47 t.

Testolactone, ENGR.z.

S.

B.

NO.

1257 Page 56 z.

14.ENR.

S.